案例分析
防止早期药物中断
IQVIA预测可能早日停止治疗的多发性硬化症患者中有81%
Nov 03, 2022
By submitting this form you agree to our使用条款隐私政策. Information provided by you may be collected and automatically stored in our database and may be used for sending you additional information about IQVIA and our services. Such information also may be transferred to IQVIA companies in other countries. Copyright © 2018-2022 IQVIA Holdings Inc. and its affiliates. All rights reserved.

确定关键的患者旅程活动that lead to early product discontinuation isan important part of product strategy- 尤其是用于慢性或长期疾病(如多发性硬化症)的治疗。

In this case study, IQVIA’s Real World Data (RWD) resources and state-of-the-art artificial intelligence (AI) and machine learning (ML) methods helped this large Biotech company to准确地识别出停用多发性硬化症治疗的高风险的患者。

战略影响:

  • 伊克维亚的AI驱动的建模成功预测了81%的患者可能早日停止治疗
  • Ourclient was able to formulate new business strategies解决已确定的问题和improve patient adherence,帮助实现其产品的真正价值

相关解决方案